Neurogan Health Launches 2% GHK-Cu Copper Peptide Body Care After 12-Week Clinical Trial Showing 32.8% Wrinkle Depth Reduction and 20–30% Skin Firmness Improvement
Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.